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Background: Drug-disease interactions negatively affect the benefit/risk ratio of drugs for
specific populations. In these conditions drugs should be avoided, adjusted, or
accompanied by extra monitoring. The motivation for many drug-disease interactions in
the Summary of Product Characteristics (SmPC) is sometimes insufficiently supported by
(accessible) evidence. As a consequence the translation of SmPC to clinical practice may
lead to non-specific recommendations. For the translation of this information to the real
world, it is necessary to evaluate the available knowledge about drug-disease interactions,
and to formulate specific recommendations for prescribers and pharmacists. The aim of
this paper is to describe a standardized method how to develop practice
recommendations for drug-disease interactions by literature review and expert opinion.
Methods: The development of recommendations for drug-disease interactions will follow
a six-step plan involving a multidisciplinary expert panel (1). The scope of the drug-disease
interaction will be specified by defining the disease and by describing relevant effects of
this drug-disease interaction. Drugs possibly involved in this drug-disease interaction are
selected by checking the official product information, literature, and expert opinion (2).
Evidence will be collected from the official product information, guidelines, handbooks,
and primary literature (3). Study characteristics and outcomes will be evaluated and
presented in standardized reports, including preliminary conclusions on the clinical
relevance and practice recommendations (4). The multidisciplinary expert panel will
discuss the reports and will either adopt or adjust the conclusions (5). Practice
recommendations will be integrated in clinical decision support systems andin.org May 2020 | Volume 11 | Article 7071
Abbreviations: DDSI, Drug-dise
Administration; ICD, International
Related Health Problems; ICPC, In
PAR, Public Assessment Report; SmP
van Tongeren et al. Practice Recommendations for Drug-Disease Interactions
Frontiers in Pharmacology | www.fropublished (6). The results of the evaluated drug-disease interactions will remain up-to-date by
screening new risk information, periodic literature review, and (re)assessments initiated by
health care providers.
Actionable Recommendations: The practice recommendations will result in advices for
specific DDSI. The content and considerations of these DDSIs will be published and
implemented in all Clinical Decision Support Systems in the Netherlands.
Discussion: The recommendations result in professional guidance in the context of individual
patient care. The professional will be supported in the decision making in concerning
pharmacotherapy for the treatment of a medical problem, and the clinical risks of the
proposed medication in combination with specific diseases.Keywords: drug-disease interactions, literature review, expert opinion, study protocol, practice recommendations,
clinical decision supportINTRODUCTION
Contra-indications are situations where a medical product must
not be given for safety reasons (European Commission; U.S.
Department of Health and Human Services Food and Drug
Administration) Depending on the patient characteristics, there
may be different reasons for contra-indications, such as
physiological conditions (age, gender, pregnancy, etc),
hypersensitivity or a concomitant disease (European
Commission; U.S. Department of Health and Human Services
Food and Drug Administration). Drug-disease interactions
(DDSIs) are situations where the pharmacotherapy used to
treat a disease causes worsening of another disease in a patient
(Merck Manual Consumer Version). In these circumstances
drugs should be avoided (i.e., are contra-indicated), adjusted or
accompanied by extra monitoring. DDSIs are common; a recent
study showed that 13.9% of all prescriptions in community
pharmacy generated a drug therapy alert regarding a DDSI
(Heringa et al., 2016). In elderly patients, 15%–16% of the
patients had at least one drug-disease interaction (Lindblad
et al., 2006; Hanlon et al., 2017). Managing of DDSI is
recommended to prevent serious harm or death (Shastay, 2017).
The official product label is an important source of
information regarding DDSIs. The European Summary of
Product Characteristics (SmPC) and the U.S. FDA label
information describe (in section 4.3 and section 4,
respectively), contra-indications (European Commission; U.S.
Department of Health and Human Services Food and Drug
Administration) However, the official product label does not take
into account that this could leave patients without treatment,
since alternatives may not be available, have proven to be
ineffective or are also contraindicated. This leaves the question
whether it is best to avoid potential risks of contraindicated drugs
and leave the disease untreated or to accept the risks to maintainase interaction; FDA, Food and Drug
Statistical Classification of Diseases and
ternational Classification of Primary Care;
C, Summary of Product Characteristics.
ntiersin.org 2the possibility of treatment. Another problem regarding DDSIs
occurs to the SmPC section 4.4 “Special warnings and
precautions for use”, and the FDA-label section 5 “Warnings
and precautions” (European Commission; U.S. Department of
Health and Human Services Food and Drug Administration).
These sections describe specific risks that should lead to a
precaution for use or informing healthcare providers. The
official product information does not always provide
information on how these risks affect these specific patient
groups. In a recent study, Weersink et al. showed that the
clinical applicability of information in the SmPC for drug use
in cirrhosis was problematic due to ambiguously formulated
information (Weersink et al., 2019). Therefore, it is unclear
whether the drug should be substituted, if the dosage should be
changed, or if additional information or monitoring is required.
A complication of the SmPC is that it is also a document with a
legal status, and has to meet the requirements that must be met
for the inclusion of warnings and prohibitions.
Patients with comorbidities are often excluded from clinical
trials, which limits the generation of evidence regarding safety of
drugs in specific patient groups (Van Spall et al., 2007; Boyd
et al., 2012; Duma et al., 2019). Even when potential risks are
detected, it is difficult to prove causality due to a low incidence of
negative outcomes related to DDSIs. Information on DDSIs is
also relatively uncommon in treatment guidelines (Dumbreck
et al., 2015). For some DDSIs however, practice guidelines are
available for specific patient populations with respect to patient
characteristics and/or pharmacokinetics, e.g., pregnancy/
lactation (Addis et al., 2000), porphyria (Thunell et al., 2007),
long QT syndrome (Woosley et al.), renal impairment (Ashley
and Dunleavy, 2018; Royal Dutch Pharmacists Association,
2019), and liver cirrhosis (Weersink et al., 2016). For other
relevant diseases, it is likewise desirable to manage DDSIs to
optimize both disease management and pharmacotherapy, and
to minimize harm. These recommendations should guide the
health care professional with respect to the clinical relevance of
the DDSI as well as the possible actions that can be considered. It
is essential that these recommendations are based on
standardized, transparent reports that summarize the availableMay 2020 | Volume 11 | Article 707
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expert opinions, and translate this into advices that are applicable
in clinical practice (Floor-Schreudering et al., 2014).
Since the 80’s, alerts for DDSIs have been introduced in
Clinical Decision Support systems in the Netherlands (De Gier,
1986; De Smet, 1988). The evaluation of potentially clinical
relevant DDSIs has evolved from different opinions of
individuals and working groups in the Netherlands to the
current national protocol that combines literature review and
expert opinion. The aim of this paper is to describe the
systematic method to develop practice recommendations for
drug-disease interactions.METHODS
Practice recommendations of DDSIs will be assessed following a
six step plan, forming a continuous circle of evaluation (Figure
1). The assessment will be performed by two pharmacist-
reviewers: experts in evaluation of the safety of drugs in the
context of clinical decision support. Both reviewers are trained in
literature review according to Cochrane methods for literature
extraction and quality assessment. A multidisciplinary expert
panel will be involved in step 1 and 4. The expert panel will
include a fixed panel with twelve health care professionals of the
following disciplines: (1) specialists who have experience in
prescribing a wide range of drugs (2 general practitioners, 1
internist/clinical pharmacologist); (2) pharmacists in primary
and clinical care (2 community pharmacists, 1 community
pharmacist/clinical pharmacologist, and 1 hospital pharmacists,
1 hospital pharmacist/clinical pharmacologist); (3) specialists
involved in professional organisations with respect to
guidelines for pharmacotherapy or clinical decision support
(n=4). Additionally, there are rotating chairs available for
additional expertise, such as physicians from the medical (sub)
specialties to be involved for specific DDSI assessments. For
example, a neurologist and psychiatrist will be added to the
expert panel to include their perspectives when evaluating a
DDSI between anti-epileptics and psychotic disorders. The
number of additional chairs will vary between specific drug-
disease interactions. Consensus will be used to achieve
conclusions. Potential conflicts of interest of the expert panel
are identified and published.
The role of the expert panel will be (A) to determine the scope
of the DDSI, and (B) to conclude about the clinical relevance and
recommendations (see step 1 and step 4 for detailed information).
Step 1: Scope of the DDSI
Scope of Disease
For every DDSI, three aspects should be identified:
1. Definition of Disease.
Internationally accepted classification systems such as
International Classification of Primary care (ICPC) (De
Smet, 1988) or International Statistical Classification ofFrontiers in Pharmacology | www.frontiersin.org 3Diseases and Related Health Problems (ICD) (WONCA)
are preferably used to specify a disease of state. For
example, a delirium and psychosis have an overlap in
clinical presentation but have a different etiology. The
expert panel should decide and motivate if in case of the
assessment of a DDSI regarding drug X and disease psychotic
disorder, data on delirium, and/or psychosis should be
included. Although diseases in literature are not always
classified using such classification systems, it is important
to specify which diseases are included.
2. Definition of Clinically Relevant Potential Effects.
A disease can worsen in various degrees. To maintain a
clear line in the assessment process of all DDSIs regarding
disease Y, the minimal level of worsening regarded as
clinically relevant should be defined. This clinical relevance
is the impact of the drug on the worsening of disease, and is
specified by (1) the impact on clinical outcomes and/or the
quality of life, and (2) the expected odds that the worsening
will happen. A rise in systolic blood pressure of 1 mmHg is
not regarded clinically relevant in patients with hypertension.
However, any seizure in previously seizure-free epilepsy
patients is generally regarded clinically relevant because of
the impact on patients’ lives.
3. Relevance of Treatment.
It needs to be determined whether the risk of a DDSI persists
after successful treatment (hypertension under control) or cure
(mamma carcinoma).
Selection of Drugs to be Evaluated
Drugs to be evaluated will be selected according to the following
sources: (1) information in the official product information
(SmPC), (2) published information in medical literature, and
(3) handbooks and professional guidelines.
1. SmPCs: All SmPCs from products marketed in the Netherlands
will be explored. The sections “contraindications” (4.3) and
“special warnings and special precautions for use” (4.4) will be
searched for drugs to be selected. When a disease is named in
one of these sections, the DDSI will be evaluated.
2. Medical Literature: for each disease a literature search will be
performed in electronic literature databases (Pubmed,
EMBASE) to identify potential drugs that may be involved
in a DDSI based on either evidence or pharmacological
profi le . Reviews about the pathophysiology and
pharmacotherapy in specific diseases will be selected for
this purpose.
3. Handbooks and professional guidelines will be searched to
identify potential drugs involved in DDSIs.
The expert panel will evaluate the drugs found in step 1–3 and
will add or remove potentially relevant drugs based on motivated
expert opinion.
In conclusion, at the end of step 1, the disease and the drugs to
be evaluated will be defined. This will be the starting point of the
evaluation of the specific drug-disease combinations.May 2020 | Volume 11 | Article 707
van Tongeren et al. Practice Recommendations for Drug-Disease InteractionsStep 2: Collection and Selection
of Evidence
For each drug, evidence will be collected with respect to the risks
of its use in the context of the disease Y. The evidence will be
clustered together for drugs that are expected to cause similar
worsening of the disease through shared pharmacological
properties based on similarities in the chemical structure and
receptor binding profile, a common pharmacological mechanism
of action and side effects profile (e.g., dihydropyridine calcium
channel blockers and antihistamines). Potential risks for the use
of drug X in disease Y can be based on the findings presented
in Table 1.Frontiers in Pharmacology | www.frontiersin.org 4Collection of Evidence
Information will be collected in the following sources:
• SmPC and Public Assessment Report (PAR): The following
sections in the SmPC will be searched for relevant
information about the DDSI: “Posology and method of
administration” (4.2), “contraindications” (4.3), “special
warnings and special precautions for use” (4.4), “side
effects” (4.8), “pharmacodynamics properties” (5.1), and
“pharmacokinetic properties” (5.2). Whenever available, the
PAR will be searched for additional information. The
registration holder will be contacted for more information if
data in the SmPC or PAR are unclear.Step 1 
Scope of the drug-disease interacon 
Step 2 
Collecon and selecon of evidence 
Step 3 
Data extracon and evaluaon 
Step 4 
Conclusion about relevance and 
recommendaons 
Step 5 
Publicaon and integraon in clinical 
decision support systems 
Step 6 
Updang 
FIGURE 1 | Flow chart of the evaluation plan.May 2020 | Volume 11 | Article 707
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guidelines about the specific disease will be searched for
information regarding the DDSI.
• Electronic Databases: A literature search will be performed in
electronic databases (Pubmed, EMBASE) using keywords for
the following search items: disease, drug name/drug class, and
terms that identify risks associated with the combination (e.g.,
avoid, risk, adverse drug reaction). In case of diseases with
very different clinical presentations, terms that will be used for
identifying the population will be aligned with the expert
panel at the end of step 1. Subheadings, Booleans, and title
words will be used to refine the strategy. Additional
publications will be added through citation tracking.
Exclusion Criteria
When a drug is contraindicated for reasons of ineffectiveness or
the availability of better treatment options, this will not be
regarded as evidence supporting a DDSI. This will be
motivated in the assessment report. Other exclusion criteria
are studies that do not involve humans and publications
lacking information on the key questions in Figure 2.
Selection of Evidence
The following criteria will be used to select the evidence:
1. Contribution to answer the research question. Generally, few
studies have been performed in the population with the
disease in question. All available publications concerning
the population at risk will be included. If not available,
publications regarding drug X causing disease Y will be
included. A specific type of papers are those describing the
potential pharmacological mechanism. These papers might
contribute to answering the research question, although they
often do not include patient data.
2. Level of evidence. We will include the publications of clinical
information with the highest level of evidence (meta-analysis,
systematic reviews, clinical trials, and other controlled
studies). Other sources, such as case reports, will be
included to underline the potential clinical relevance. TheFrontiers in Pharmacology | www.frontiersin.org 5quality of the evidence concerning the population at risk was
evaluated by grade 1 to 4 based on established criteria for
drug-drug interactions that were used in previous studies
(Van Roon et al., 2005), slightly adjusted for DDSIs (Table 2).
Other studies and data were evaluated quantitatively.
The exact search strategy and criteria for the selection of
literature will be motivated in every DDSI report. Table 2.
Step 3: Data Extraction and
Evaluation
Extraction
For every DDSI assessment, summary tables will describe the
following characteristics and results of the included information:
study type, number of patients with and without disease Y, drug
regimen, outcomes, and level of evidence of the study. The
outcomes will describe the identified risks, including severity of
the disease and statistics if present. Additional risk factors are
presented quantitative whenever available.
Summary tables will also present the relevant data originating
from the SmPC and relevant data from handbooks and
or guidelines.
Evaluation
The data obtained in step 3 will be presented as an assessment
report with motivated answers to the following questions: (a) is
there a clinically relevant DDSI, and (b) is an alert required in
clinical decision support systems.
a. The data will be considered in the context of the patients at
risk for a clinically relevant interaction between drug X and
disease Y (Yes/No) using the criteria determined in the scope
of the DDSI (see step 1). When evidence for specific
formulations is lacking, pharmacokinetic data, and data on
systemic effects will be reviewed and used to decide whether
extrapolation is justifiable. In all the reports, the reviewers will
evaluate if the additional risks can be attributed to the
individual drug or the entire drug class. The evaluation will
be based on literature and pharmacologic characteristics ofTABLE 1 | Findings suggestive of a drug-disease interaction.
Finding Example
Drug X causes worsening of disease Y Aggravation of psoriasis by beta-blockers
Drug X causes symptoms related to disease Y Mania symptoms caused by corticosteroids
Drug X causes an increased risk to develop disease Y Higher frequency of ischemic strokes in patients using combined oral
contraceptives
A theoretical relation exists between the pharmacological characteristics of drug X and the
pathophysiology of disease Y
Potentially harmful stimulation of dopamine receptor D2 by dopamine
agonists in schizophrenia.FIGURE 2 | Key questions in drug-disease interactions.May 2020 | Volume 11 | Article 707
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formulated.
b. When sufficient evidence of a clinically relevant interaction
between drug X and disease Y is available, another question
will be answered: does the DDSI require an alert in the clinical
decision support systems (Yes/No)?
Alerts are often overridden which is partly caused by their
appearance in situations without peril or not requiring action
(Van der Sijs et al., 2006; Isaac et al., 2009; Nanji et al., 2014).
Alerts can be irrelevant when a risk has already been weighed
against the benefits by the prescriber. This situation may occur
when (1) appropriate guidelines have been established and are
implemented, (2) the need for treatment outweighs the potential
risk and the risk is properly monitored, and/or (3) when both
drug X and disease Y are prescribed and treated by a specialized
discipline. For example, when there is a DDSI between a
cardiovascular drug and a cardiovascular disease, an alert may
not be needed when the drug is only prescribed by cardiologists,
the effect is mild, and there are no alternatives available. In these
situations, the assessment report motivates the reason why the
DDSI does not require a drug alert for clinical decision support.
When an alert is required, an alert message will be proposed
with information about the clinical risk, risk factors and decision
support. Risk factors are factors that are associated with a higher
probability of the occurrence of the clinical risk. The decision
support consists of four types of advice that will be composed for
the specific DDSI (Table 3). Multiple advices can exist for the
same drug, depending on the indication, prescriber, and context,Frontiers in Pharmacology | www.frontiersin.org 6since the benefit/risk ratio may differ. Decision support advices
(Tables 3:2–4) may include dose adjustments. Table 4
summarizes factors considered for deciding on a drug alert and
if deemed necessary, the content of the advice. The content and
design of the extraction forms were piloted and reviewed for
feasibility by the expert panel.
Step 4: Conclusion About Relevance and
Recommendations
The expert panel is provided with all used information and
decides on the literature selection criteria (step 2), summary, and
conclusions of the literature, the proposed categorization and
contents of the advice (step 3). The reports will be supplemented
with expert opinions generated in the discussions. These may
also involve evaluation of current handling of the (presumed)
DDSI and practical implications of the proposed handling; every
discipline should be able to practice the decision support advice.
If there are different opinions within the expert panel, these will
be included as comments in the assessment report. The expert
panel will conclude by consensus. The conclusion will be
included in the reports.
Step 5: Publication and Integration in
Clinical Decision Support Systems
The assessment reports will be published in Dutch guidelines for
DDSIs (Borgsteede et al., ; Royal Dutch Pharmacists Association,
2019). The advices will be integrated in the national drug databases
G-Standaard and PharmabasePro in The Netherlands. Hence,
they will be adopted in all Dutch Healthcare Information
Systems supporting prescribing and dispensing processes in
hospitals as well as primary care. Whenever drug X will be
prescribed/dispensed to a patient labelled with disease Y, an
alert will be generated automatically when deemed necessary as
decided in step 3 and 4. Relevant background information
concerning the advices will be accessible from the clinical
decision support system and available on the websites of the
guidelines for DDSIs and will include a reference to the
assessment report. The format of an assessment report is
included in Appendix 1 in Supplementary Material
Step 6: Updating
Three main pathways are identified for keeping the assessment
reports, related advices, and background information up-to-date:
1. New drugs and new risk information on existing drugs will be
screened to identify eligible drugs to be submitted in step 1 of
the assessment procedure. New risk information is defined as
a news item from the regulatory authorities (Dutch
Medicines Evaluation Board, European Medicines Agency).TABLE 2 | Quality of Evidence for drug-disease interactions (DDSIs).
Definition Score
Meta-analyses, systematic reviews, randomized controlled trials with clinically relevant endpoints 4
Controlled trials in patients with surrogate endpoints; observational studies 3
Well documented case reports; case series 2
Incomplete published case reports (no re- or de-challenge, presence of other explaining factors for the adverse reaction) 1May 2020 | Volume 11 | ArticTABLE 3 | Types of decision support advices and factors considered for
assigning an advice to a Drug-disease interaction (DDSI).
1. Avoid drug X in disease Y.
2. Avoid drug X unless carefully considered by the specialist treating disease Y.
Monitor DDSI effect.#
3. Avoid drug X, unless there is no alternative available. In that case, monitor
DDSI effect.#
4. Monitor DDSI effect.##Dose adjustment optional.TABLE 4 | Factors considered for assigning an advice.
- Availability of alternatives for drug X
- Severity of effect DDSI
- Relation between the disciplines involved in prescribing drug X and disciplines
treating disease Y
- Ability to monitor the DDSI effect
- Risk factorsle 707
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step 1. When the results of step 1 have changed, new
assessment reports may have to be written. When the
results of step 1 have remained the same, the existing
reports will only be updated with new literature published
after the previous search. In this case, step 3 and 4 are more
focussed on whether the earlier made decisions are affected
by new evidence or changes in medical practice (e.g., patients
monitoring their own blood pressure instead of monitoring
by the doctor). For every new drug a new assessment report
will be written.
3. Health care providers can also initiate a (re)assessment. This
situation may particularly occur when medical practice has
changed.Ethics
As there were no patients nor data directly derived from patients
involved in our methodology, this protocol was not evaluated by
an ethics committee. Also, there were no privacy issues with
respect to study data applicable.
Implications
Not all drug-disease combinations will be associated with clinical
questions about safety of medications and dose recommendations.
To develop the relevant recommendations for DDSI, we will need
input from clinical practice for drug-disease combinations they
experience clinical problems. Moreover, a multidisciplinary expert
panel needs to be initiated to develop recommendations. Finally,
drug databases need to implement this knowledge in their
database and be able to transfer this to Clinical Decision
Support Systems in hospitals and primary care.ACTIONABLE RECOMMENDATIONS
We expect that the development of practice recommendations
will result in advices for specific DDSI. The content and
considerations of these DDSIs will be published in national
guidelines, professional journals, and international scientific
journals. To enhance the application in clinical practice, the
DDSIs will be implemented in all Clinical Decision Support
Systems in the Netherlands.Frontiers in Pharmacology | www.frontiersin.org 7Anticipated Results
A summary will be made to present the findings of all drugs
evaluated in the context of a DDSI. This summary will consist of
the description of the disease with in- and exclusion criteria, and
the substance names of medications that have been evaluated for
potentially clinical DDSI, with a conclusion and motivation if the
DDSI is considered relevant (see Table 5). The summary will also
present recommendations how to act if these medications are
prescribed, e.g., if the combination can be used safely, if dose
adjustments are necessary and if monitoring of the patient is
required. The motivation includes pharmacological
considerations and experts opinions. All results will be
published in national guidelines. Recommendations that need
specific professional attention will be published in national
professional journals. If recommendations will give a
significant contribution to international perspectives of
medication safety and translation of knowledge to clinical
practice, we aim to publish in international journals as well.
Implementation in Clinical
Decision Support
Finally, the recommendations for clinical decision support will
be implemented in the two National Drug Databases in the
Netherlands (Pharmabase and G-Standaard). As information of
these databases is used in all Health Care Information System in
primary care and hospitals, this approach will guarantee a
nationwide implementation of the developed DDSIs.DISCUSSION
We have developed a systematic method to develop practice
recommendations for DDSIs. This method will provide
standardized reports of combined evidence and expert
opinions about DDSIs, that can be adapted to the specific
demands and criteria that might differ between diseases. This
protocol facilitates transparent communication about the
scientific and clinical motivations of potential DDSIs, and their
relevance for decision support in patient care.
The strengths of this method are the combination of evidence
and expert opinion, the multidisciplinary character of the advices
and the integration in clinical decision support systems. First,
there is often limited evidence available in DDSIs, which makes it
more important to rely on expert opinions; the clinical and
pharmacological experience complement the evidence. Second,
the multidisciplinary character of the expert panel ensures that
the proposed advices include the available knowledge and
experience, and are applicable for all disciplines. Third, the
specific actions suggested by alerts of decision support systems
enforces implementation in daily practice. These advices are
integrated in all Dutch clinical decision support systems for
prescribers and pharmacists, in primary and secondary care. This
can be regarded as a limitation, since international dissemination
is desirable. To support international dissemination, we have
published our study protocol and will publish the results of DDSI
assessments in international scientific journals as a first step toTABLE 5 | Summary of findings for a drug-disease interaction.
Disease
Date conclusion expert panel: dd/mm/yyyy
Description of disease with in- and exclusion criteria
Drugs evaluated
Drug name
(generic)
DDSI
(yes/no)
Drug alert
required (y/n)
Motivation Practice
recommendation
Drug (class) 1
Drug (class) 2
….May 2020 | Volume 11 | Article 707
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that it is more time consuming compared to individual opinions,
or a single literature source such as the SmPC. However, this
effort will result in DDSIs that are evidence and expert-opinion
based, and hence we believe the recommendations will be better
accepted in clinical care.
However, these assessments cannot replace the information
in the SmPC. Where the SmPC should provide information on
all potential DDSI, a specific evaluation should reveal the clinical
relevance of and conclude about the meaning for clinical
practice. Integration of all possible risks regarding DDSIs in
clinical decision support systems will lead to a drug alert
overload. Important drug alerts may be accidentally
overridden, a consequence that is known as “alert fatigue”
(Van der Sijs et al., 2006; Heringa et al., 2016). By discussing
the risk of alert fatigue in advance, as this method proposes, the
benefit of an alert in terms of contribution to drug safety to the
risk of alert fatigue is carefully weighed and therefore increases
the specificity of drug alerts. This method is complementary to
other proposed strategies for reducing alert fatigue, such as
individualization of drugs alerts by incorporating more patient
characteristics (Van der Sijs et al., 2006; Heringa et al., 2016),
using other triggers (e.g., new laboratory values, worsening of
disease) (Van der Sijs et al., 2006; Heringa et al., 2016) and
clustering signals consisting of the same advices (Heringa
et al., 2017).
A previous study has shown that in one-third of patients one
or more DDSI alerts were not generated due to missing data in
pharmacy practice (Floor-Schreudering et al., 2013). Physicians,
pharmacists and patients should co-operate to identify missing
drugs and diseases in electronic health records. By allowing
patients and health care providers to have access to and
suggest changes in their electronic health records, the problem
of missing data can be overcome. This enables the handling of
DDSIs as proposed by the assessments resulting from
our protocol.
The assessments resulting from our protocol will produce
advices for health care providers, albeit patients should also be
involved in the handling of DDSIs; DDSIs should always be
considered in the context of the individual patient, and these
kind of decisions should ideally be the result of shared decision
making (Oshima Lee and Emanuel, 2013). Patients are always
affected by the handling of DDSIs, through the impact of changes
in the proposed drug regimen, extra monitoring by their
physician (e.g., more consults, blood tests), and/or worsening
of symptoms. They also have a prominent role in monitoring
their own symptoms and contacting the health care providerFrontiers in Pharmacology | www.frontiersin.org 8when the disease deteriorates. Proper informing of patients is
therefore essential. Although there are concerns that negative
expectations may cause adverse effects and decrease the efficacy
of a drug (the “nocebo effect”) (Bingel, 2014), a recent systematic
review pointed out that there is currently not enough evidence
for a negative impact of informing patients about side effects
(Jose and AlHajri, 2018). It is however important to consider
factors that may affect the understanding of information and the
related expected outcomes, such as the format (e.g., multimedia
approaches) and health literacy (Peters et al., 2011; Jose and
AlHajri, 2018).
Methods have been designed for determining the clinical
relevance of drugs risks, such as drug-drug interactions (Van
Roon et al., 2005) and anticancer drug interactions (Jansman
et al., 2011). This protocol matches these existing methods and
therefore complements the scientific basis of clinical
decision support.
Evaluated DDSIs will lead to scientific publications about these
DDSIs using this protocol, and knowledge integrated in decision
support followed by interventions that will eventually improve
drug management. Future research should focus on (a) closing the
current knowledge gaps, (b) the degree of compliance and reasons
to differ from the advices, and (c) the patient outcomes.
In conclusion, the procedure of a structured evaluation of
DDSIs is described. The advices will generate clinical decision
support for healthcare professionals based on available evidence
and expert opinion, which enables optimal patient care. Finally,
this will also identify gaps in existing knowledge in DDSIs that
will form a research agenda for future investigations.AUTHOR CONTRIBUTIONS
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